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The glucagon-like peptide 1 receptor (GLP1R) is a G protein-coupled
receptor (GPCR) involved in insulin synthesis and regulation; there-
fore, it is an important drug target for treatment of diabetes.
However, GLP1R is a member of the class B1 family of GPCRs for
which there are no experimental structures. To provide a structural
basis for drug design and to probe class B GPCR activation, we
predicted the transmembrane (TM)bundle structureofGLP1Rbound
to the peptide Exendin-4 (Exe4; a GLP1R agonist on the market for
treating diabetes) using the MembStruk method for scanning TM
bundle conformations. We used protein–protein docking methods
to combine the TMbundlewith theX-ray crystal structureof the 143-
aa N terminus coupled to the Exe4 peptide. This complex was sub-
jected to 28 ns of full-solvent, full-lipid molecular dynamics. We ﬁnd
14 strong polar interactions of Exe4 with GLP1R, of which 8 inter-
actions are in the TM bundle (2 interactions conﬁrmed by mutation
studies) and 6 interactions involve the N terminus (3 interactions
found in the crystal structure). We also ﬁnd 10 important hydropho-
bic interactions, of which 4 interactions are in the TM bundle (2
interactions conﬁrmed by mutation studies) and 6 interactions are
in the N terminus (6 interactions present in the crystal structure).
Thus, our predicted structure agrees with available mutagenesis
studies. We suggest a number of mutation experiments to further
validate our predicted structure. The structure should be useful for
guiding drug design and can provide a structural basis for under-
standing ligand binding and receptor activation of GLP1R and other
class B1 GPCRs.
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Gprotein-coupled receptors (GPCRs) are the largest family ofintegral membrane proteins within the human genome, and
they are all characterized by seven transmembrane (TM) helices,
with the N terminus on the extracellular (EC) side and the C ter-
minus on the intracellular (IC). This family of proteins senses
molecules outside of the cell and activates signal transduction
pathways to cause cellular responses. Because of this vital role in
cellular signaling networks, GPCRs are involved in many diseases,
and they are the target of∼40%of all prescription pharmaceuticals
on the market (1). Because of the importance of GPCRs as drug
targets, it is vital to gain structural information for aiding in drug
design. Unfortunately, GPCRs, like other membrane proteins, are
difﬁcult to crystallize. There are now X-ray crystal structures for
more than 12 distinct receptors of the (at least) 800 humanGPCRs
(2–16). All of the crystallized receptors belong to the class A
(rhodopsin-like) family of GPCRs. However, a phylogenetic
analysis of GPCRs classiﬁes them into different subfamilies: class
A (rhodopsin-like), class B1 (secretin-like), class B2 (adhesion-
like), class C (glutamate-like), and Frizzled/Taste2 (12).
Class B1 (secretin-like) GPCRs are activated by peptide hor-
mones. The large ectodomain of these receptors interacts strongly
with the C-terminal halves of their endogenous polypeptide ago-
nists. The N terminus of their ligands putatively binds to the TM
bundle and EC loops. The current structural understanding of
ligand binding and activation of class B1 GPCRs comes from
functional and ligand binding studies as well as the crystallized
ectodomains of several class B1 GPCRs (17–19). These studies
have put forth speculations as to the plausiblemechanisms for class
B1 GPCR agonist binding and activation initiation, but in the ab-
sence of atomic-level structures of these receptors, it is difﬁcult to
understand, probe, and expand on these activation hypotheses.
In this work, we focus on the glucagon-like peptide 1 receptor
(GLP1R). Activation of GLP1R by GLP1 stimulates the adenylyl
cyclase pathway, which increases insulin synthesis and release of
insulin in a glucose-dependent fashion (20). In addition, GLP1
reduces body weight by increasing satiety in the brain (21). Con-
sequently, GLP1 would seem to be attractive for treating both
type 2 diabetes and obesity. However, GLP1 is rapidly degraded
by the serine protease dipeptidyl peptidase-IV in the body,
resulting in its half-life of only 1–2min (22, 23). Exendin-4 (Exe4),
a 39-aa peptide isolated from the venom of the Gila monster, is
a more stable analog of GLP1 with a half-life of 2.5 h in its mar-
keted form (24–26). It has a 50% sequence homology with GLP1,
and it is a full agonist with a stronger afﬁnity and potency for
GLP1R (27). Indeed, Exe4 is currently on the market for treat-
ment of diabetes. Despite the success of Exe4 and its derivatives,
there is still a need to develop small-molecule (nonpeptide) orally
active agonists of GLP1R. This need is further supported by recent
reports of oncogenic side effects of Exe4 (28). The process of novel
drug design targeting GLP1R could be aided signiﬁcantly if there
was a structure of the full GLP1R bound to Exe4, which is the
motivation of the research reported here. Our structure also pro-
vides testable hypotheses of GLP1R activation on ligand binding.
In the following sections, we present the predicted structure of
the full membrane-bound GLP1R/Exe4 complex in the presence
of water. The TM bundle was predicted using the MembStruk
methodology (29). This bundle, which was attached to the GLP1R
ectodomain crystallized with partial Exe4 (30), was inserted into
a periodic membrane-water box and relaxed by molecular dy-
namics (MD). We ﬁnd that this predicted structure is consistent
with all available mutation data, and we suggest additional ex-
perimental tests to validate key aspects of our structure.Webelieve
that this structural information presented should help the de-
velopment of selective active small-molecule agonists for GLP1R
and also aid in probing the activation of class B1 GPCRs.
Methods
We have been developing methods for predicting the structures of GPCRs
since the late 1990s. The earlier methodology, denoted as MembStruk, fo-
cused on sequential optimization of the seven TM helices starting from
a homology template (29). More recently, we have developed a method,
denoted as GEnSeMBLE, that aims at a combinatorially complete set of helix
rotations and tilts (31). The structure that we report here was built entirely
using MembStruk several years ago, but it was not published. We applied
our GEnSeMBLE methodology to the older MembStruk structure, but we
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obtained essentially the same packing of the seven TM helices (more details
are in SI Methods, section 8 and Tables S1 and S2). Therefore, we decided to
continue with our previous structure for the seven TM helix bundle and its
connection to the N terminus, but we replaced the previously homology-
built ectodomain of the N terminus of GLP1R (nGLP1R)/Exe4 part (where
nGLP1R is the N terminus of GLP1R) with its crystal structure, which
appeared recently (30).
A summary of the full procedures used to generate the GLP1R/Exe4 can
be given in the following nine steps (the procedure is depicted in Fig. 1).
i) The initial step in MembStruk (29) is to use comparative hydrophobicity
analysis of GLP1R and related GPCRs to identify the seven likely TM
domains and then, position (x, y, z) the hydrophobic centers of these
helices on a common plane with preselected tilts (θ, φ) and axis rotations
(η) based on some template (in this case, we used the predicted prosta-
glandin D2 (PGD2) receptor structure) (32).
ii) This step is followed by sequential optimization of each TM domain
by varying η over 360° in 30° increments and side chain optimization
(SCREAM with modest minimization) (33) in a sequence that considers
all TM domains multiple times.
iii) Because of the large 143-aa N terminus of GLP1R, we originally built the
structure for nGLP1R from homology to the NMR structure of the mouse
Corticotropin-releasing factor (CRF) receptor 2 (Protein Data Bank ID
code 2JND). This 131-aa region then underwent optimization of the side
chains (34).
iv) We used the ZDOCK procedure (35) to dock the NMR structure of the
full Exe4 ligand (Protein Data Bank ID code 1JRJ) to the nGLP1R struc-
ture from step iii (36).
v) We manually docked the nGLP1R/Exe4 complex from step iv to the TM
bundle in such a way that the N terminus of the ligand could interact
with the TM region from step i.
vi) We connected the N terminus to the TM region (residues 131–145) and
built the three EC and three IC loops using Modeler; this process was
followed by SCREAM to position the side changes and then, energy
minimization (37).
vii) Then, we inserted the full GLP1R protein into a periodic membrane and
water box (75 × 75 × 117 Å), eliminating overlapping species to obtain
a system with 61,119 atoms. This system was equilibrated at 300 K (ﬁrst,
the water and membrane and then, all atoms for 20 ns) using NAMD
2.6, with CHARMM22 charges for the protein and CHARMM27 charges
for the lipids (38–40). The waters were modeled using the TIP3P poten-
tial function (41).
viii) In the meantime, an X-ray crystal structure had appeared for nGLP1R
bound to part of Exe4 (9–39; Protein Data Bank ID code 3C5T) (42). We
matched this structure to our predicted structure and reoptimized
(SCREAM, minimization, and MD for 18 ns).
ix) After 18 ns of full-atom and full-solvent MD, we performed simulated
annealing of the TM portion of the ligand binding site, and then, we
carried 10 ns of full-atom and full-solvent MD at 300 K. A representative
snapshot of the ﬁnal 10 ns of MD was chosen for the discussion below.
Experimental information was not used during any of the above steps,
except that information known about GLP1 loop structures was used to select
loops from Modeler in step vi. The speciﬁc information used is discussed in SI
Methods, section 4.
Results and Discussion
Intraprotein Interactions. For class A GPCRs, several conserved
interhelical interactions, such as the 1-2-7 or 2-3-4 hydrogen bond
networks, are present in most crystal structures. The amino acids
involved in the 1-2-7 and 2-3-4 interactions are not conserved in
classBGPCRs.However,wedoﬁndmany interhelical interactions,
some of which occur between residues conserved in class B1
GPCRs, which may be important for their structure and function.
The GLP1R/Exe4 complex has 16 hydrogen bonds within its TM
bundle (excluding helix-forming hydrogen bonds) or connecting
loops, which is shown in Table S3 and discussed in the following
sections. The TM bundle interactions are pictured in Fig. 2.
TM3-TM6 ionic lock. We consider that the conserved E247(TM3)-
R348(TM6) ionic lock is analogous to the R(3.50)-D/E(6.30)
[using Ballesteros numbering of TM residues (43)] ionic lock of
class A GPCRs known to stabilize the GPCR in an inactive form,
although these donor and acceptor residue types are swapped in
the class B1 version of the TM3-TM6 ionic lock (44). We ﬁnd this
ionic lock to be maintained through most of the dynamics. This
interaction could play the role of maintaining the inactive form of
class B1 GPCRs. Indeed, E247 is fully conserved among class B1
GPCRs, whereas R348 is either an R or K in all class B1 GPCRs.
This hypothesis could be tested by mutations that break the ionic
lock, which might lead to a constitutively active receptor (GLP1R
does not exhibit constitutive activity) (45). This hypothesis is
complicated in the light of GLP1R studies like the work by Heller
et al. (46), which looked at the R348G mutant of GLP1R and
found no activation for all concentrations of GLP1; in contrast,
the work by Takhar et al. (47) found R348A to have no effect on
binding or activation of GLP1. Perhaps, these large changes to
alanine or glycine led to a modiﬁed TM bundle that changed the
binding site, and/or this residue is critical for G-protein coupling
and activation. A more subtle R348Q mutation would test the
intricacies of this ionic lock in more detail.
Because the TM3-TM6 ionic lock is present in our structure, it
is likely that our complex is not yet fully activated. However, our
structure is bound to an agonist, and TM6 makes almost no
interactions other than this ionic lock. Thus, it may be at least
partially activated. This lack of TM6 interactions would allow
TM6 (on breaking of the ionic lock) to immediately move away
from TM3 to interact with the Gα-subunit of the G protein,
which it does in the active conformation of the G protein-bound
β2-adrenergic receptor structure (48).
Coupling of TM2-TM3-TM6. The 3-6 ionic lock is additionally coupled
to TM2 by the conserved N182(TM2)-E247(TM3) hydrogen bond,
resulting in a TM2-TM3-TM6 (2-3-6) hydrogen bond network [N182
(TM2)-E247(TM3)-R348(TM6)]. ThisN182(TM2)-E247(TM3) has
only minor ﬂuctuations through the course of dynamics. Because
N182 is an N, H, or Q in class B1 GPCRs, this 2-3-6 hydrogen bond
network may be conserved in class B1 GPCRs. The 2-3-6 conserved
network may be further stabilized by the similarly conserved R190
(TM2)-N240(TM3) hydrogen bond, which is shown in conjunction
with the 2-3-6 network in Fig. 2. We suggest that this interaction
might be analogous to the 2.45(S/N/T)-3.42(S/N/T)-4.50(W) con-
served interaction of class A GPCRs. Indeed, N240(TM3) is just 7
aa away from E247(TM3) compared with the 3.42 residue in class
A GPCRs, which is 8 aa away from the 3.50 residue. We ﬁnd the
R190(TM2)-N240(TM3) interaction to be very constantly main-
tained throughout the dynamics. N240 is fully conserved among
class B1 GPCRs, whereas R190 is R, K, or N, and therefore, this
interaction is possible in any class B1 GPCR and may be a feature
of this receptor class.
TM1-TM2-TM7 interaction network. The remaining two strong and
conserved interactions between TM1 and TM7 [Y152(TM1)-Q394
(TM7)] and TM2 and TM7 [R176(TM2)-E408(TM7)] might play
an analogous role to the TM1.50(N)-TM2.50(D)-TM7.49(N) inter-
actions conserved among class A GPCRs. Perhaps it is important to
keep the TM1-TM2-TM7 (1-2-7) region rigid to control activation.
Both interactions are stable during the course of the dynamics
Fig. 1. Creating the GLP1R/Exe4 bundle. The steps used to create our
GLP1R/Exe4 structure are depicted along with the methods used at each
point. After the steps shown here, the entire complex was optimized
through 28 ns of MD.
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simulation. These residues are also conserved in class B1 GPCRs:
Y152 may be a Y or H, whereas Q394 may be a Q or H. R176 and
E408 are fully conserved in all class B1 GPCRs. Note that the R176
(TM2)-E408(TM7) interactions are located in the IC end of the
TMs, and as such, they could also play a role in GPCR activation.
We ﬁnd two additional interactions in the 1-2-7 region that in-
volve nonconserved amino acids—T149(TM1)-E387(TM7) and
H180(TM2)-S163(TM1)—that further stabilize the 1-2-7 coupling.
We ﬁnd that the T149(TM1)-E387(TM7) interaction is only tran-
sient during dynamics, being oftenmediated by theH1 residue of the
ligand. Perhaps the agonist will eventually break this interaction as
part of activation. The H180(TM2)-S163(TM1) interaction forms/
breaks/reforms several times during the course of dynamics, in-
dicating that it is less stable than the hydrogen bonds discussed
previously. Despite their transience, these hydrogen bonds do help to
stabilize the coupling of the 1-2-7 helices, and in conjunction with the
with the more stable conserved interactions discussed earlier, they
form a solid grouping of TMs 1, 2, and 7. The two conserved inter-
actions discussed above, along with these two nonconserved inter-
actions, are pictured in Fig. 2.
EC loop couplings and N-terminal interactions. The remaining four
interhelical interactions are between the EC loops. The ﬁrst
three interactions are with D222(EC1) and adjoining EC2 resi-
dues R299, W297, and C296. In addition, there is a helical region
present in EC1 from residue 215 to 225. It is the base of this helix
that interacts with EC2. The ﬁnal interloop hydrogen bond is
between H374(EC3) and M303(EC2). The EC loops are clearly
closely coupled, and they provide order to the ﬂexible loop
regions, which has been seen in other GPCR crystal structures
(49). These stabilizing interactions would play a role in peptide
binding, because they need to accommodate a peptide reaching
from the N terminus past EC1 and into the TM bundle interior.
Finally, GLP1R also has the TM3-EC2 disulﬁde coupling (C296-
C226) conserved among class A GPCRs and class B1. There are
no other Cys residues in the EC loops.
The overall architecture of the N terminus from the crystal
structure remains stable during the course of the dynamics. There
are still the three conserved disulphide bonds, two regions of an-
tiparallel β-sheets, and an α-helix adjacent to the ligand, which all
occur in all of the class B1 GPCR N-terminal crystal structures
(50). No signiﬁcant deviations from the crystal are observed.
Overall, our study of GLP1R shows that there are several
conserved hydrogen bond networks that mimic those networks of
class A GPCRs. The 3-6 ionic lock is similar to the lock of class A
GPCRs, although it may play a somewhat different structural and
functional role in G-protein activation. The 1-2, 1-7, and 2-7
networks mimic the 1-2-7 interaction motif of class A GPCRs.
Finally, the loop structures, which may have direct bearing on li-
gand binding, are stabilized by several interloop interactions.
Protein–Ligand Interactions. Structure overview. The GLP1R/Exe4
binding site involves interactions throughout the N terminus, TM
regions, and EC loops with the primary interactions occurring with
the N terminus, TMs 1, 2, and 7, and EC1 (Fig. 3). We ﬁnd Exe4 to
be helical from residues 9–29. The strongest interactionswith theN
terminus include six polar interactions (three of which were pres-
ent in the crystal structure) and six hydrophobic interactions (all
were present in the crystal structure). The TM bundle features
eight polar interactions (two of which were conﬁrmed by mutation
studies) and four hydrophobic interactions (two of which were
conﬁrmed by mutation studies). The full-energy analysis for these
interactions is shown in Table S4.Wewill discuss the binding site in
three parts: hydrogen bonds, nonpolar interactions, and detailed
comparison with mutation data.
Polar interactions. We ﬁnd 14 polar interactions (hydrogen bonds or
salt bridges) betweenGLP1R and Exe4 (Fig. 4 and Table 1). There
are eight polar interactions within the TMregion, which reﬂects the
primary areas of interaction between the ligand and TM bundle:
TMs 1, 2, and 7 as well as EC1. The TM region polar interactions
are particularly focused at the ﬁrst few residues of the ligand—
speciﬁcally H1 and E3 but also, T5 and F6. Our TM bundle
interactions are also validated by site-directed mutagenesis studies
for residues T149, E387, T391, and K197, which we ﬁnd to interact
with H1 and E3 of the ligand (14, 51) as shown in Table 1.
Our ﬁve N-terminal interactions include the two crystal salt
bridges: E128(N)-R20 and E127(N)-K27 (42). These two resi-
dues’ importance has also been shown through mutation studies
on E127 and E128 (52). In addition, we ﬁnd three very strong
interactions of the N terminus, of which two interactions are in
the ﬂexible region between the structured N terminus and TM1
and the third interaction is at the C terminus of the ligand. The
remaining crystal hydrogen bond between R121(N) and the
backbone of K27 alternates during the MD from water-mediated
Fig. 2. The (A) TM2-TM3-TM6 and (B) TM1-TM2-TM7 conserved hydrogen
bond networks. (A)We believe that the E247(TM3)-R348(TM6) ionic lockmay
be associated with the unactivated GPCR structure (analogous to the R3.50-
D/E6.30 interaction in class A GPCRs). TM3 is additionally coupled to TM2
through the conserved N182(TM2) to form a 2-3-6 interaction. This in-
teraction is further stabilized by the R190(TM2)-N240(TM3) hydrogen bond,
whichmay be analogous to the TM2.45(S/N/T)-3.42(S/N/T)-4.50(W) conserved
interaction of class A GPCRs. (B) We also see several more transient couplings
between TM1, -2, and -7, which are shown here. These four interactions help
solidify the local structure of TMs 1, 2, and 7, and their disruption may be
involved in activation.
Fig. 3. Overview of the ligand binding site’s hydrophobic (A) and hydro-
philic (B) interactions. GLP1R is shown with a color transition from black to
white as the protein goes from the N terminus to the C terminus. Exe4 is
shown in red. Hydrophilic interactions are shown in A, with protein residues
in blue and ligand residues in turquoise. Hydrophobic interactions are shown
in B, with protein residues in green, and ligand residues in yellow.
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interaction to a weak hydrogen bond. This weak interaction is
consistent with a study by Underwood et al. (53), which found
that mutating R121 to alanine (R121A) decreased ligand binding
by only 1.6-fold.
Hydrophobic interactions. We predict 21 strong hydrophobic inter-
actions between GLP1R and Exe4. The 10 strongest interactions
(cutoff of −3 kcal/mol for the van der Waals (VDW) energy; 1
kcal= 4.18 kJ) are shown in Fig. 5 andTable S5.We ﬁnd twomain
clusters of hydrophobic interactions.
The ﬁrst cluster of hydrophobic interactions occurs in EC1.
GLP1R residues W203, M204, Y205, A209, W214, and L217
interact with Exe4 residues L10 and M14. Indeed, experiments
on residues M204A/Y205A found a 2.7-fold decrease in binding
of Exe4 (54). We ﬁnd that M204 has a −7.0 kcal/mol interaction
energy with Exe4, whereas the interaction energy of Y205 with
Exe4 is −2.6 kcal/mol.
The second cluster of hydrophobic interactions occurs on one
face of the helical portion of Exe4, interacting with the hydro-
phobic face of a helix of GLP1R in the N terminus. These
interactions include the interactions between GLP1R residues
L32, T35, V36, W39, Y69, Y88, L89, P90, W91, and L123 and
Exe4 residues V18, V19, F22, L23, L26, P31, and P36. These
interactions include some of the strongest hydrophobic inter-
actions in our entire structure: L32 at −8.4, W39 at −6.6, P90 at
−4.2, and W91 at −4.0 kcal/mol. These interactions were all
present in the crystal structure of nGLP1R/Exe4, and they have
been conﬁrmed by mutation studies (42, 53). Speciﬁcally, the
L32A mutation had a 7.1-fold effect on Exe4 binding and 9.5-
fold effect on activation, whereas P90A had a 2.1-fold effect on
binding and 5.5-fold effect on activation.
We also ﬁnd a ﬁnal small cluster of nonpolar residues in the
middle of TM3 (L232, M233, and V229; not pictured), which
form a hydrophobic pocket around the G2 residue of Exe4.
These hydrophobic interactions, plus the K202-E17 salt bridge,
and the weaker polar interactions with EC1 in Table S4 (to Q210
and Q211) indicate clearly that EC1 is extremely important for
Exe4 binding.
Comparison with mutation data. Several mutation studies have been
carried out on Exe4 with the intent of determining the residues
that are important for ligand binding (51–55). These studies are
summarized in Table S6. Of the 26 mutations leading to a de-
crease in binding or activity, 24 mutations are consistent with our
predicted equilibrium structure, whereas the remaining 2 muta-
tions appear transiently during the course of the dynamics. Of
these 26 residues, 13 residues involve the N terminus (and were in
the X-ray structure), whereas 13 residues involve the TM helices
and EC1; 11 of these 13 residues interact with six of seven TMs
(all but TM6) plus EC1. The remaining two residues on TM6
(H363 and E364) are transiently involved in a hydrogen bond
network that spans the middle of the TM bundle and extends to
H1 of the ligand. Our prediction agrees with the conclusion of
mutation studies that D198 is not crucial for ligand binding (56).
It is important to emphasize that the GLP1R structure (except
for the N terminus) was derived strictly from our MembStruk
method without any use of mutation data (except in the loop
growing, which used a distance constraint between Y205(EC1)-
Fig. 4. Exe4hydrogen bondswith theN terminus (A)
andTMregionofGLP1R (B). All of the receptor–ligand
hydrogen bonds are depicted here and quantiﬁed in
Table S3. Protein residues are shown in blue [Corey-
Pauling-Koltun (CPK) drawing method], whereas li-
gand residues are shown in red (licorice drawing
method). We ﬁnd a total of 14 important polar
interactions of Exe4 with GLP1R, of which 6 inter-
actions involve the N terminus (A; including 3 inter-
actions found in the X-ray crystal structure) and 8
interactions are in the TM bundle or loops (B; in-
cluding 2 interactions that have been conﬁrmed by
mutation studies).
Table 1. Polar interactions between GLP1R and Exe4
GLP1R residue Location Exe4 residue Energy Mutation Reduces binding
TM region interactions
T149 TM1 H1 −1.0 T149M (47) 5.0-fold
E387 TM7 H1 −6.2 E387A (48) 3.9-fold
T391 TM7 H1 −2.8 T391A (48) 2.8-fold
K197 TM2 E3 −39.6 K197A (48) 3.0-fold
K383 TM7 E3 −37.9
Q211 EC1 T5 −1.0
Q210 EC1 F6 −3.1
K202 EC1 E17 −48.8
N-terminal interactions
R134 N E16 −47.6
E128 N R20 −44.8 E128A (29) 2.4-fold*
E139 N K12 −38.4
E127 N K27 −33.4 E127A (29) 6.8-fold*
R40 N S39 −23.3
Energies are given in kilocalories per mole and are provided to show the relative strength of the interactions.
*Present in the crystal structure of nGLP1R/Exe4.
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F6 and requiredM204, Y205, D215, andR227 to be close to some
part of Exe4).
Finally, we note that our structure preserved all interactions
found in the crystal structure—both hydrophilic and hydrophobic—
over the course of the dynamics. This ﬁnding provides additional
validation of our structure, because these interactions would be
expected to be stable. In addition, all residues indicated in the lit-
erature to be potentially important for binding or activation are
found in our structure to point into the TM bundle, or they are
otherwise accessible to the ligand. As such, they can either interact
with the ligand itself or have structural effects. Overall, our GLP1R
structure strongly agrees with the available experimental data,
making it valuable for further structural and activation studies.
Testing the Predicted Binding Site. Our predicted structure of
GLP1R and its binding site for Exe4 suggest many mutation
studies for its further validation. Indeed, we constructed struc-
tures for 14 such mutations (Table S7 shows their effects on
energies). The procedure was to use SCREAM to introduce the
desired mutation and then minimize the protein to 0.5 kcal/mol
per angstrom rms force (33). These calculations assumed that
the overall backbone structure remains intact. Of 14 mutations, 2
mutations are predicted to improve binding, whereas 12 muta-
tions are predicted to decrease binding.
The ﬁrst set of mutations was chosen with the goal of validating
our predictions of the strongest interactions between GLP1R
and Exe4. Ten cases were aimed at disrupting the binding site by
breaking interactions discussed previously: R134A/Q, K202A/Q,
and K383A/Q break salt bridges or hydrogen bonds, whereas
W203N/Y and W214N/Y disrupt the EC1–ligand hydrophobic
interactions. We also suggest two ligand mutations that would de-
crease binding: K12A and M14Q. The K12A mutation would lose
the E139 salt bridge, whereas the M14Q would disrupt the hydro-
phobic network that theM14 has in the EC1 area. In each of the 12
cases, our predicted change in binding agrees with expectation.
Finally, we predicted twomutations to improve ligand binding. The
ﬁrst mutation was S11Wof Exe4, which allows a new interaction to
be formedwithW214on the receptor. The second change isQ213K
of GLP1R, which forms a new hydrogen bond with D9 on Exe4.
Both of these changes improve our predicted interaction energies
between the receptor and ligand.
Discussion of Ligand Binding and Protein Activation. Our GLP1R/
Exe4 structure suggests several general features of ligand binding
to GLP1R and potentially, class B1 proteins as a whole. One
feature is that we ﬁnd that the TM region polar interactions are
particularly focused at the ﬁrst few residues of the ligand—spe-
ciﬁcally, H1 and E3 but also, T5 and F6. This ﬁnding is in accor-
dance with the known importance of the N terminus (speciﬁcally
residues 1–7) of class B1 agonists for protein activation (50). In the
speciﬁc case of Exe4, if the ligand is truncated by eight residues, it
becomes a competitive antagonist for GLP1R, because it can still
bind the receptor but no longer cause activation (27).
Next, we ﬁnd that the binding pocket of Exe4 shows strong polar
and hydrophobic interactions with EC1. Experimental studies
showed that mutations of EC2 residues to alanine dramatically
decreased binding of GLP1 but had no effect on the binding of
Exe4 (57), consistent with our structure. We suggest that the rea-
son for the importance of the loops in the peptide binding is to
align the ligand in the correct conformation for TM bundle entry.
In the two-domain model of class B1 GPCR protein binding, the
N-terminal ectodomain plays the role of recognizing the ligand and
supports the initial binding (58).We believe that the next step is for
the ﬂexible N terminus/ligand complex to align itself to the TM
bundle by loop interactions followed by ﬁnal insertion of the head
region of the ligand into the TM bundle itself.
Also, we note that theﬂexibleN terminus of the ligand is nestled in
the TM1-TM2-TM7 binding pocket, which leaves the TM3-TM4-
TM6 region largely open, making this area available for binding of
small molecules serving as ago-allosteric modulators (59). In addi-
tion, the residues of the ligand inserted themselves between hydro-
gen bonds of the apo GLP1R [for example, T149(TM1)-H1-E387
(TM7)]. This ﬁnding suggests that part of the effect of Exe4 binding
may be to break some of the TM1-TM2-TM7 strong interactions,
giving the structure the ﬂexibility to achieve its active conformation.
Any discussion of GPCR activation would be incomplete with-
out mention of the TM3-TM6 ionic lock, of which we ﬁnd a vari-
ation in our structure. Instead of the conserved R(3.50)-D/E(6.30)
ionic lock of class AGPRCs, we ﬁnd an analogous conserved E247
(TM3)-R348(TM6) ionic lock. Breaking this interaction may be
crucial for GLP1R activation. To test this hypothesis, one could
mutate one of the charged residues to a polar residue, such a glu-
tamine; and therefore, the overall hydrophilicity of the region
could be preserved, but the interaction would be broken.
Finally, it has been suggested that an N-terminal helix capping
motif of a peptide agonist is a key element underlying class B1
GPCR activation (18). This structural feature is theorized to
consist of a hydrophobic interaction between residues 6 and 10,
and it is stabilized by a salt bridge between residues 7 and 10 of the
ligand. The result of these interactions is that the ligand forms an
L-shape at its N terminus. Although we do not see the exact 7–10
and 6–10 interactions—instead, we ﬁnd that residues Phe6 and
Ser8 form a backbone hydrogen bond—this alternate interaction
causes the ligand to adopt a slightly more loose L-conformation.
This structural constraint may be important for the rational drug
design of peptide agonists targeting class B1 receptors.
Conclusion
We present here the predicted TM bundle for GLP1R (residues
146–408), which we combined with the crystal structure for the
N terminus (residues 28–145) and Exe4. The resulting structure
was then equilibrated in an explicit membrane and water envi-
ronment for 28 ns. We ﬁnd strong agreement with available ex-
perimental data, most of which played no role in the predictions.
We suggest 14 mutations to provide strong tests of our predicted
binding site. This structure can now form the basis for the
Fig. 5. Hydrophobic interactions between GLP1R
and Exe4 in the N terminus (A) and EC1 (B). Protein
residues are shown in blue (CPK drawing method),
whereas ligand residues are shown in red (licorice
drawing method). We ﬁnd 10 important hydro-
phobic interactions, of which 6 interactions are in
the N terminus (A; all conﬁrmed by X-ray crystal
structure) and 4 interactions are in the TM bundle
(B; of which 2 interactions have been conﬁrmed by
mutation studies).
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rational design of other peptide ligands and the greatly needed
small-molecule ligands.
The model that we present here can be used to explore the
mechanisms of class B1 GPCR binding and activation (52). In
addition, we expect that this structure will provide a basis for the
design and optimization of new small-molecule ligands that bind
selectively and speciﬁcally to GLP1R.
Finally, one of the grand challenges in understanding GPCRs
is to elucidate the mechanism of activation. This study does not
address this issue directly; however, we do identify a TM3-TM6
ionic lock that is conserved across class B1 GPCRs that we be-
lieve may play a very similar or more complex role in GLP1R
activation compared with the TM3-TM6 ionic lock conserved
across a subset of class A GPCRs. Mutation studies on this ionic
lock will help test such speculations and provide structural sig-
natures of active and inactive receptor conformations.
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